03/09/2025
An authoritative paper published by the US NIH, "Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity," by renowned scientist Daniel J. Drucker, rigorously and scientifically acknowledges that the positive effects of GLP-1 products on fat loss and diabetes treatment far outweigh their potential negative effects, making them a relatively safe and effective method for fat loss. We also consulted with this scientist during product development to optimize the ratio of active ingredients, achieving the most effective weight loss while minimizing negative side effects.👇
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indicatio...
